Cardiovascular Systems Stock
Your prediction
Pros and Cons of Cardiovascular Systems in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cardiovascular Systems vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cardiovascular Systems | - | - | - | - | - | - | - |
| SI-BONE Inc | -1.530% | 9.167% | 18.018% | -20.606% | -22.485% | - | - |
| Lantheus Holdings Inc | -1.830% | 2.817% | 19.346% | 22.346% | 53.147% | 4.435% | - |
| Cryolife Inc. | 0.000% | -8.901% | -43.506% | -31.361% | -55.442% | 25.180% | -26.271% |
News
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
Key Points
- Interested in BioAge Labs, Inc.? Here are five stocks we like better.
- BioAge Labs said its lead drug BGE-102 is on track for near-term data in two areas: a Phase 2 cardiovascular
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results
Johnson & Johnson’s (NYSE: JNJ) price action entered consolidation in early March. While it may continue moving sideways or even pull back further, those moves are unlikely, given a convergence of